The nisms by which these metabolic disturbaes occur are not fully understood; however, several factors have been identified which are able to mimic the effects of cachexia ecperimentally. In generaL inflammatory cytokines have been shown to play a major role in the alterations in metabolism seen in these disease states. Tumour necrosis factor-a (TNFa), interleukin-1 (IL-10), interleukin-6 (IL-6) and interferons-a and -7 have all been shown to increase hepatic lipogenesis and serm triglyceride levels (Feingold and GrunfeKl, 1987; Grunfeld et al., 1988 Grunfeld et al., , 1991 Darling et al., 1990; Feingold et al., 1991; Blackham et al., 1992; Ettinger et al., 1992; Furlong et al., 1992; Arias-Diaz et al., 1993; Memon et al., 1993; Stassman et al., 1993), and in some cases reduce triglyceride ckarance (Beutler et al., 1985; Noguchi et al., 1991) . Antibodies to these cytokines have been shown to ameliorate the effects on lipid metabolism when sepsis is experimentally induced by injection of lipopolysaccharide (LPS) in animals (Tracey et al., 1987; Memon et al., 1993; Strassman et al., 1993), and in cachexiainducing tumour models (Sherry et al., 1989; Lgstein et al., 1991), demonstrating that alterations in lipid metabolism as a result of diwase are ideed mediated at least in part by inflammatory cytokines. Further, circulating wles of cytokines have been demonstrated to be elevated in AIDS (Gunfeld and Feingol 1992a,b), some forms of cancer (Balkwill et al., 1987; Jablons et al., 1989; Stovroff et al., 1989 ) and sepsis (Fong et al., 1990) al., 1990), and inhibitors of the synthesis of prostaglandin and platelet-activating factor (Welbourn and Young, 1992) but none has been completely successful in altering metabolc imbalances or increasng survival. Because of the well-known role of L-carmtie as a carrier of long-chain fatty acids into the mitochondrial matrix for oxidation (for review, see Bremer, 1983) , it has recently been hypotheised that administration of carnitine to septic or cachectic patients could increase the rate of oxidation of fatty acids and normalise lid metabolism. Carnitine administration has been shown to rele the symptoms of carniine-deficient humans (Worthley et al., 1983) and increase the survival of endotoxic rats (Takeyama et al., 1989) . This laboratory recently demonstrated that carnitine administration to LPS-injected rats increased survival and food consumption, and decreased plasma triglycerides and hepatic lipogenesis (Gabo et al., 1993). Mehanisms of carnitie effects in sepsis are still unknown, as in vitro rates of oxidation in isolated mitochondria from livers of LPS-injected rats were not increased by in vivo administration of carnitine.
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In the studies presented in this paper, we investigated whether carnitine had an effect on the level of inflammatory cytokines which are generally increased in sepsis and cachexia and are known to affect lipid metabolism. We uilised both an LPS-induced model of septic shock in rats (Takeyama et al., 1989; Gallo et al., 1993) and a rat methykholanthreneinduced sarcoma model previously demonstrated to cause cachexia (Burt et al., 1981; Popp et al., 1981; Moley et al., 1985) . We studied the effects of carniie administration on plasma levels of TNF-a, IL-10 and IL-6, as well as triglycerides, in each of these models. Cytokine measurement Plasma cytokine (TNF-m, IL-l and IL-6) levels were determined by enzyme-linked immunosorbent assay following fractionation of plasma by high-performance capillary electrophoresis (HPCE) as described previously (Phillips and Kimmel, 1994 Cytokines TNF-a, IL-lp and IL-6 were measured in the plasma of carnitine-treated and control LPS-injected rats (Table I) . Preliminary measurements of cytokine levels made 1, 3 and 5 h post-LPS injection indicated that plasma cytokine levels peak 3 h post-injection. Therefore, for these suies, cytokine levels were detrmined in plaa taken from rats 24 h before LPS injection and 3 h after LPS injection. Levels of all three inflammatory cytokines were decreased in carnitine-treated rats. The reduction of TNF-s was statistically significant.
MCA-induced sarcoma model
Physical characteristics Rat body weight and food consumption were monitored daily throughout the experiment, and tumour weight was obtained after sarifice on day 28 (Table H) Figre 4 Plasma carnitine concentrations in osmotic pumpimplanted tumour-bearing rats. Carnitine concentrations were determined in plasma from tumour-bearing rats taken 28 days post-tumour implantation (a). Rats were implanted with the carnitine-filled osmotic pumps 7, 14, 21 or 28 days before assay. Carnitine concentration was determined weekly in the plasma of a single tumour-bearing rat that was implanted with the tumour and osmotic pump simultaneously (b). Plasma carnitine concentration decreased over the course of the experiment, suggesting that the pump did not deliver carnitine at the same rate continuously.
almost control level over the next 3 weeks. The failure of carmitine treatment to decrease TG levels for longer than 7 days after pump implant was probably related to the decreased level of circulating carnitine. Most pumps (in place for longer than 7 days) appeared, upon removal, to be obstructed by host tissue growth, and it is likely that carnitine delivery was decreased over time.
Cytokines Plasma from non-TB control, TB control and all carnitine-treated TB rats was obtained 28 days post-tumour implantation, and analysed for levels of TNF-a, IL-l and IL-6. No correlation between tumour burden and cytokine concentration was observed (r = 0.29 for TNF-a). Results are presented in Table III oxidation, and hypertnriglyceridaemia. The primary purpose of these studies was to determine whether carnitine had any therapeutic effect on lipid metabolism in rat models of septic shock and cancer-induced cachexia.
It has been shown previously that treatment with carmitine decreases illness and increases survival in rats suffering from sepsis after injection with lipopolysaccharide (LPS) (Takeyama et al., 1989; Gablo et al., 1993) . Carnitine treatment has also been shown by this laboratory to lower serum TG levels and decrease hepatic lipogenesis in LPS-injected rats significantly (Gallo et al., 1993) . In this study, we examined the effect of carnitine on lipid metabolism in a model of cancer cachexia, and found that carnitine-treated tumourbearing rats had significantly lower levels of serum TG than did untreated tumour-bearing rats (Table III and Figure 3) . This finding together with our previous results suggests that carnitine does have a normalising effect on lipid metabolism in both sepsis and tumour models of cachexia.
The mechanism by which carnitine lowers serum TG levels in cachexia is currently unknown. Given the well-defined role of carnitine in fatty acid oxidation, it was hypothesised that carnitine decreased TG levels in disease models by increasing fatty acid oxidation. However, in vitro studies with isolated mitochondria from carnitine-treated septic rats showed no difference in oxidation rates from untreated septic rats (Takeyama et al., 1989; Gablo et al., 1993) . These results suggest that the carnitine effect may not be explained by an increase in mitochondrial oxidation of fatty acids in vivo. This is not a definitive finding, as it is possible that carnitine was washed out of the mitochondria during isolation for in vitro study. In addition, this laboratory has shown that liver carnitine levels are increased following LPS injection, even when no carnitine therapy is given, indicating that hypertriglyceridaemia that may result from decreased fatty acid oxidation is not the consequence of insufficient levels of carnitine (Gabo et al., 1993) . Thus, the mechanism by which carnitine relieves hypertriglyceridaemia and other symptoms of sepsis and cachexia may be different from its necessary role in fatty acid oxidation.
Several inflammatory cytokines, such as TNF-x, IL-l1, and IL-6, have been shown to be mediators of hypertriglyceridaemia and other symptoms observed in both LPSinduced sepsis and cancer cachexia. Because serum levels of these cytokines are often elevated in septic shock (Fong et al., 1990 ) and sometimes in cachexia (Balkwill et al., 1987; Jablons et al., 1989; Stovroff et al., 1989) , and can play major roles in lipid metabolism, we decided to examine whether carnitine had any effect on cytokine levels in our rat models of LPS-induced septic shock and methylcholanthrene-induced sarcoma cachexia. We found that carnitine did lower serum levels of inflammatory cytokines in both models. In the LPS model, carnitine therapy resulted in reduced levels of all three cytokines measured, significantly lowering TNF-a and decreasing IL-lp and IL-6 (Table I ). In the sarcoma model, TNF-x and IL-l were significantly reduced in the carnitinetreated TB rats (Table III) . These results suggest that carnitine plays a role in controlling the level of circulating cytokines, which in turn have an effect on lipid metabolism. In fact, other groups have shown that carnitine reduces circulating cytokines in surgical patients (Delogu et al., 1993) and also reduces TNF-a secretion by stimulated human polymorphonuclear cells (Fattorossi et al., 1993 studies will examine the mechanism of the reduction of cytokine levels by carnitine. and will begin by determining whether carnitine lowers cytokine levels by increasing clearance of cytokines, or by reducing production of cytokines.
